Company Active LTD

Company profile

Lif Nano RX Ltd

Lif Nano RX Ltd is a UK company with status active founded in 2013 based in Yorkshire and the Humber.

CRN
08551193
Founded
2013
Age
10

Overview

Legal name
LIF NANO RX LTD
Region
Yorkshire and the Humber
Registered address
Unknown
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

1 event
31 May
2013

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2015
Funded years
2015, 2017, 2020
Age at first award
1 years

Projects

2020 Collaborative R&D Lead participant

A SYNTHETIC BIO-MIMETIC TO TREAT CANCER: Patent protection of UK's global lead in cell-free Immune Oncology.

1 Nov 2020 to 30 Apr 2021

Awarded
£98,919
Total cost £98,919

COVID-19 HAS INTERRUPTED PATENT PROTECTION OF A NOVEL ANTI-CANCER BIO-MIMETIC * Applicant LIFNanoRx (LNT) has invented an IL-6-based bio-mimetic nanoparticle to treat cancer, exemplified by "IL-6-MOF". * PATENT PROTECTION is urgent : Government lock-down due to COVID-19 prevented essential prototype production and testing to underpin the Patent. * This Pr...

2020 Collaborative R&D Lead participant

MULTIPLE SCLEROSIS: Recovery of UK's strong lead in protecting the MS Brain by securing UK-Based formulation of LIFNano™

1 Oct 2020 to 30 Sep 2021

Awarded
£104,002
Total cost £130,003

PROTECTING THE BRAIN IN PEOPLE WITH MULTIPLE SCLEROSIS (MS) * **MS** is a demyelinating autoimmune disease that attacks the brain, with year-on-year loss of brain volume, starting late teens and becoming manifest late twenties. There is no cure. Current therapies are immunosuppressive only. * The COVID-19 pandemic has spotlighted the vulnerable young incl...

2017 Collaborative R&D Lead participant

CELL-FREE REGENERATIVE MEDICINE: Nano-Engineered "LIFNano" to treat Multiple Sclerosis

1 Jan 2017 to 31 Dec 2018

Awarded
£174,998
Total cost £249,997

NANOMEDICINE (NanoMed) is a new era in medicine that exploits nano-engineering to deliver the right dose of therapy to the right place, at the right time. LIF is a growth factor important for maintaining brain health and the SME "LNT" has pioneered NanoMed for delivery of LIF as a revolutionary approach to treat the devastating autoimmune disease MULTIPLE...

2015 GRD Proof of Concept Lead participant

Preclinical Proof of Concept for LIF Nanotherapeutics for the Treatment of Multiple Sclerosis

1 May 2015 to 31 Jan 2017

Awarded
£99,991
Total cost £212,160

MULTIPLE SCLEROSIS Multiple Sclerosis (MS) is a disabling neurological condition commonly affecting young adults and involving 100,000 people in the UK alone. Damage or scarring of the myelin sheath - demyelination - is the hallmark of MS that progressively or intermittently causes a wide range of symptoms as specific nerves become inflamed and lose funct...

Product types

Collaborative R&D GRD Proof of Concept